Description and Brand Names
Drug information provided by: Micromedex
US Brand Name
Tositumomab and iodine I 131 tositumomab combination regimen is used to treat patients with CD20-positive, relapsed or refractory non-Hodgkin's lymphoma. It is also given to patients with non-Hodgkin's lymphoma who already have received rituximab.
This medicine is to be given only by or under the immediate supervision of your doctor.
The tositumomab and iodine I 131 tositumomab combination regimen will be withdrawn from the United States market on February 20, 2014.
This product is available in the following dosage forms: